Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Olliaro, Piero L ^a   Merle, Corinne ^a,b   Mthiyane, Thuli ^c   Bah, Boubacar ^d   Kassa, Ferdinand ^e   Amukoye, Evans ^f   N'Diaye, Alimatou ^g   Perronne, Christian ^h   Lienhardt, Christian ^a,i   McIlleron, Helen ^j   Fielding, Katherine ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d Hopital Ignace Deen   (Guinea)

^e Centre National Hospitalier de Pneumo Phtisiologie   (Benin)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g Programme National de Lutte Contre le SIDA   (Senegal)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

Cardiotoxicity; Fluoroquinolones; Gatifloxacin; Mycobacterium tuberculosis; QT interval

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATTRIBUTABLE RISK; BODY TEMPERATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; FACTOR ANALYSIS; FEMALE; FOLLOW UP; HEART RATE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MODEL; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGED; DRUG EFFECTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; BODY TEMPERATURE; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; HEART RATE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 85021632438     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01834-16     Document Type: Article

References (14)

1. Garnett CE, Zhu H, Malik M, Fossa AA, Zhang J, Badilini F, Li J, Darpo B, Sager P, Rodriguez I. 2012. Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J 163:912–930. https://doi.org/10.1016/j.ahj.2012.02.023.
2. Owens RC, Jr, Ambrose PG. 2005. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41(Suppl 2):S144–S157. https://doi.org/10.1086/428055.
3. Sanguinetti MC, Jiang C, Curran ME, Keating MT. 1995. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299 –307. https://doi.org/10.1016/0092-8674(95)90340-2.
4. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. 2001. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 59:122–126.
5. Center for Drug Evaluation and Research. 2012. Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions and answers (R1). Center for Drug Evaluation and Research, US Department of Health and Human Services, Silver Spring, MD.
6. Department of Health and Human Services, Food and Drug Administration. 2005. International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Fed Regist 70: 61134–61135.
7. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, Dejong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro P, Lienhardt C. 2014. 2014. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371:1588 –1598. https://doi.org/10.1056/NEJMoa1315817.
8. Anderson ME, Mazur A, Yang T, Roden DM. 2001. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 296:806–810.
9. Hagiwara T, Satoh S, Kasai Y, Takasuna K. 2001. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol 87:231–234. https://doi.org/10.1254/jjp.87.231.
10. Akita M, Shibazaki Y, Izumi M, Hiratsuka K, Sakai T, Kurosawa T, Shindo Y. 2004. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 29:63–71. https://doi.org/10.2131/jts.29.63.
11. Murphy ME, Singh KP, Laurenzi M, Brown M, Gillespie SH. 2012. Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation. Int J Tuberc Lung Dis 16:144–149. https://doi.org/10.5588/ijtld.11.0074.
12. World Health Organization. 2004. Treatment of tuberculosis guidelines for national programmes. WHO/CDS/TB/2003.313. World Health Organization, Geneva, Switzerland.
13. Smythe WA. 2016. Characterizing population pharmacokinetic/pharmacodynamic relationships in pulmonary tuberculosis infected adults using nonlinear mixed effects modelling. PhD thesis. University of Cape Town, Cape Town, South Africa.
14. Smythe W, Merle CS, Rustomjee R, Gninafon M, Lo MB, Bah-Sow O, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson US. 2013. Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using Monte Carlo simulations. Antimicrob Agents Chemother 57:4164–4171. https://doi.org/10.1128/AAC.00479-13.